<DOC>
	<DOCNO>NCT03000335</DOCNO>
	<brief_summary>Previous finding show biomarker comprise three microRNAs ( miRs ) miR-451 , miR-151-5p miR-1290 independently predict precursor B-cell acute lymphoblastic leukemia ( B- ALL ) patient ' risk relapse measure cell bone marrow ( BM ) aspiration take diagnosis ( Avigad et al. , 2016 : Genes , Chromosomes &amp; Cancer 55:328-339 ) . Curewize Health recognize development minimally invasive blood test frequent long-term monitoring greatly benefit pediatric precursor B-ALL patient . Therefore , current study investigate monitoring ability miR-451 , miR-151-5p miR-1290 measure blood sample . The study perform two stage : Stage 1-Cross-Sectional Study : Blood sample collect relapsed pediatric B-ALL patient B-ALL patient remission . Blood collect patient three tube , serum , plasma whole blood analysis , order interpret best blood source measure miR-451 , miR-151-5p miR-1290 . The level miRs blood compare relapse B-ALL patient B-ALL patient remission . If Stage 1 Cross-Sectional study successful , investigator continue clinical trial Stage 2 Prospective Monitoring study . Stage 2-Prospective Monitoring Study : Blood collect patient diagnosis routine clinical follow-up . Patients five year diagnosis . The source blood find optimal measure miR level Stage 1 collect . The final design Stage 2 study decide completion Stage 1 study .</brief_summary>
	<brief_title>Evaluation ProALL miRs Blood Specimen Prediction ALL Relapse Risk</brief_title>
	<detailed_description>1 . Acute Lymphoblastic Leukemia Risk Based Treatment : Children ALL usually treat accord risk group define clinical laboratory feature . This approach allow child sign historically good outcome treat modest therapy spar intensive toxic treatment , allow child historically low probability long-term survival receive intensive therapy may increase ALL patient ' chance cure . Study group use vary criterion , strong emphasis minimal residual disease ( MRD ) measurements quantify number leukemic cell remain patient treatment . The widely use MRD assay base polymerase chain reaction ( PCR ) amplification antigen-receptor gene , flow cytometric detection abnormal immunophenotypes ( Campana , 2010 ) . These technique identify patient ' specific leukemia clone bone marrow induction treatment measure number residual leukemic cell post-induction . Two widely use example Risk stratification protocol Berlin-Frankfurt-Munster ( BFM ) Protocol Europe Children 's Oncology Group Protocol USA . 2 . Previous ProALL miR Findings : The ProALL prototype assay microRNAs ( miRNAs ) ( Avigad et al. , 2016 ) discover microarray analysis hybridization BM aspirate take diagnosis 48 ALL patient 979 different miRNAs . The down-regulated expression level miR-451 miR-151-5p up-regulated expression level miR-1290 associated adverse prognostic factor . The second study focus measure three miRs BM sample take B-ALL patient diagnosis treat BFM protocol . ProALL miRs predict high risk relapse ( p &lt; 0.0001 , n=127 ) . ProALL miRs find independent predictor test prognostic factor know diagnosis test PCR-MRD . Similar finding find patient treated DCOG protocol ( n=32 , p &lt; 0.0001 ) . In small feasibility study investigator show ProALL miRs measure blood correlate ProALL miRs measure bone marrow ( Avigad et al . Mir Expression Profile Peripheral Blood Lymphocytes Predicts Relapse Pediatric Acute Lymphoblastic Leukemia . Blood . 2016 ; 128:1736 - Poster presentation ASH 2016 ) . 3 . Study Rationale : Though MRD greatly contribute substantial increase ALL patient ' survival outcome , nearly 15 % 20 % young ALL patient eventually succumb relapse , result relapse ALL 4th common childhood malignancy ( Locatelli et al. , 2012 , Pui et al. , 2012 , Hunger Mullighaan , 2015 ) . Once relapse occur 30 % 50 % relapsed patient cure even intensive chemotherapy bone marrow transplantation ( Nguyen et al . 2008 Locatelli et al. , 2012 ) . Relapsed ALL patient high MRD prior hematopoietic stem cell transplantation ( HSCT ) significantly bad probability disease-free survival 10 year relapse treatment begin ( Eckert et al. , 2015 ) . Therefore , stand reason early detection relapse large increase MRD improve relapse patient disease-free survival . Yet , many oncology group n't incorporate monitor ALL treatment protocol labor intensity MRD measurement ; invalidation feasibility routine MRD monitoring . This due factor variable kinetics leukemic cell regrowth ( van Dongen et al. , 2015 ) , nearly 50 % ALL patient succumb relapse new leukemia clone identify diagnosis ( Choi et al. , 2007 ) . The frequency monitoring may also limit , especially child , due discomfort practical difficulty pose BM aspiration ( Coustan-Smith E. et al. , 2002 ) . A simple predictive test ALL blood would increase practicality test ALL patient frequently may eventually lead prevention relapse mean preemptive treatment . Investigating ProALL miRs measure blood , addition BM , predict relapse risk ALL patient vital due many advantage blood test . If ProALL level test frequently blood probability successfully treat patient ' leukemia increase potentially enabling physician take preemptive measure prevent predict relapse . 4 . Study Design : The study perform two stage : Stage 1-Cross-Sectional Study : Blood sample collect relapsed pediatric B-ALL patient B-ALL patient remission . Three Blood sample collect patient tube order interpret best blood source measure miR-451 , miR-151-5p miR-1290 . The source test serum , peripheral blood lymphocyte whole blood . The level miRs blood compare relapse B-ALL patient B-ALL patient remission ( n=30 ) . If `` Stage 1 Cross-Sectional '' study successful , investigator continue clinical trial `` Stage 2 Prospective Monitoring '' study . Stage 2-Prospective Monitoring Study : Blood collect patient diagnosis and/or routine clinical follow-up . Patients five year diagnosis ( nâ‰ˆ65 *3 sample ) . One source blood collect . Patients follow 3 year . The final design Stage 2 study completion Stage 1 study . 5 . Sample Size Considerations : Stage 1 Cross-Sectional Study : For sample size calculation Primary end-point test ability ProALL miRs measure blood differentiate B-ALL patient remission patient relapse . The sample size calculation accord Sampling : comparison proportion MedCalc ( MedCalc Statistical Software version 16.1 ( MedCalc Software bvba , Ostend , Belgium ; http : //www.medcalc.org ; 2016 ) . Type 1 error 0.05 Type 2 error 0.20 . Data sample size calculation obtain DCOG cohort Avigad et al. , 2016 , choose model feasibility study due small size ( n=32 ) . Cross sectional analysis DCOG cohort show significantly patient relapse event ( p=0.001 , Fisher Exact test ) positive least one miR ( 78 % ) compare patient relapse event ( 13 % ) . Data take Figure 6 ( Avigad et al. , 2016 ) : - Patients Relapse - At least one miR positive rate 0.78 - Patients Remission - No miR positive rate 0.13 - Relapse/Remission 0.39 - The minimum number enrollee need : . Patients Relapse - n=8 b . Patients Remission - n=21 . B-ALL patient include study five year diagnosis . After complete enrollment cross-sectional study , PI query Remission/Relapse status patient . Above minimum number patient enrol . Up 12 patient relapse 31 patent remission enrol . Stage 2 Prospective Study : The sample size calculation accord Sampling : survival analysis ( Time-to-Event ) MedCalc . Type 1 error 0.05 Type 2 error 0.20 . Data sample size calculation obtain Figure 3A Kaplan Meir curve ( Avigad et al. , 2016 ) . - Survival rate Profile B 0.77 - Survival rate Profile A 0.29 - Profile B/Profile A 17 - Number enrollee need 62 At least 3 sample 3 time point take patient . A sample take relapse 2nd 3rd sample . Patients Stage 1 continue Stage 2 . The final design study Stage 1 . 6 . Blood Extraction Handling Samples : No 0.8 mL blood per kilogram enrollee 's weight collect one visit . The total amount blood collect Stage 1 7.5 mL 10.5 mL accord follow : . - PaxGene Tube - 2.5 mL - Tube Plasma - 2.5 mL 4 mL - Tube Serum - 2.5 mL 4 mL 7 . Biomarker Results Clinical Data Flow : - The blood sample screen ProALL miRs Curewize Lab . - Curewize receive clinical data correspond visit screen blood sample take send clinical site blood sample 's miR value . 8 . Statistical Analysis Plan ( SAP ) Stage 1-Cross Sectional Study : Blood Biomarker Variables : - miR-451 relative expression ( ddCt ) level - miR-151-5p relative expression ( ddCt ) level - miR-1290 relative expression ( ddCt ) level Covariates : - Age - Gender - MRD-PCR - BFM risk - Treatment group - White blood cell count diagnosis blood collection routinely test . - Steroid response - Cytogenetic variable Cross-Sectional Analysis : Stage-1 consider exploratory use design analysis Stage-2 . Variables test normality Shapiro Wilk 's test . The level expression miR-451 , miR151-5p miR-1290 compare patient remission patient relapse Mann-Whitney U test . Continuous data depict box plot show median interquartile range . Logistic regression use test miR value [ nominal ( positive/negative ) continuous ] variable compare patient remission patient relapse . The optimal combination Classifier create accord analysis . Categorical variable summarize frequency table , indicate number frequency miR status ( positive versus negative ) . Data compare Fisher exact dichotomous ( 2x2 table ) value chi-square chi-square trend table . Odds ratios likelihood ratio calculate . Receiver operate characteristic curve create , independent variable miR-451 miR-151-p , miR-1290 dependent variable relapse remission . Receiver operate characteristic curve create combined Classifier . Additional analysis perform result plan analysis give reasonable warrant . 9 . Statistical Analysis Plan ( SAP ) Stage 2-Prospective Study Will create report result Stage-1 Cross Section Study . 10 . Ethical Considerations The study conduct accord principle World Medical Association Declaration Helsinki Ethical Principles Medical Research Involving Human Subjects JAMA . 2013Í¾310 ( 20 ) :2191-2194 accordance local GCP regulation .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<criteria>Written inform consent give clinical trial subject subject 's legally acceptable representative . Patient final diagnosis BALL Male Female Age 2 19 year diagnosis . Patient remission least 3 month start treatment . Patient five year diagnosis baseline visit . Patient relapse start treatment relapse . Patient weigh least 9.4 kg . Discovery alternative disorder Bcell acute lymphoblastic leukemia . The subject know human immunodeficiency virus ( HIV ) , hepatitis B surface antigen , hepatitis C antibody dangerous contagious disease .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>microRNA</keyword>
	<keyword>relapse</keyword>
	<keyword>blood</keyword>
	<keyword>vitro diagnostics</keyword>
	<keyword>prediction</keyword>
	<keyword>lab test</keyword>
</DOC>